Name: Ep176: David Roblin on Building a TechBio Company by The Long Run with Luke Timmerman
Duration: 1 h 19 min 28 s
Description: David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

Ep176: David Roblin on Building a TechBio Company

Kevin Parker, co-founder and CEO of South San Francisco-based Cartography Biosciences, on finding new targets for cancer drugs.

Ep177: Kevin Parker on Finding Targets for Cancer Drugs

Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.

Ep177: Kevin Parker on Finding Cancer Drug Targets

Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.

Ep178: Peyton Greenside on ML-Guided Biologics Discovery

Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.

Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes

John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA

Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.

Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer

Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.

Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science

Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.

Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Ep176: David Roblin on Building a TechBio Company

The Long Run with Luke Timmerman

Related tracks